Science

UK government takes $500 million stake in space exploration firm OneWeb

As part of a consortium that includes Indian telecom Bharti Global, the UK government will invest $500 million and take a “significant equity share” in space exploration firm OneWeb, it announced Friday. OneWeb, which has its headquarters in the UK, filed for Chapter 11 bankruptcy protection in the US in March, after it was unable to secure financing. Bharti Global also will invest $500 million as part of the deal. OneWeb is one of several companies working on an Internet-from-space project, using a combination of low-altitude satellites to beam internet connectivity to ground terminals on Earth’s surface. It was slated to launch a constellation of 650 spacecraft, and its plans included providing internet coverage for the Arctic. So far, it has launched 74 satellites for the project. Frida...

President Buhari gets Madagascar herbal formula

President Muhammadu Buhari on Saturday at the State House, Abuja, received Covid Organic, the Madagascan native formulation against the COVID-19 pandemic. Samples of the solution were delivered to him by President Umaro Sissoco Embalo of Guinea Bissau who brought them along as part of the traditional medicine shared to African nations by the government of Madagascar. According to a statement issued by Garba Shehu, Senior Special Assistant to the President (Media & Publicity) in Abuja, President Buhari however reiterated that he will listen to science before allowing traditional or any new medicines to be administered on Nigerians. He said his position on all such herbal or traditional medicinal postulates had remained the same. “We have our institutions, systems and processes in the co...

Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine

Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...